News

The market for stroke rehabilitation continues to advance as existing players and new entrants offer novel therapeutic approaches and pursue commercial development. There appears to be room in this space for vendors of both implanted and noninvasive neurotech therapies. Earlier this month, CorTec GmbH, a European manufacturer of active implantable medical technologies, announced the successful seco…

The road to developing a viable visual neuroprosthetic system to restore sight has been long and difficult. But several vendors remain in the game and much of the activity involves cortical stimulation approaches. At last month’s NANS annual meeting, Nader Pouratian, professor and chair, department of neurological surgery at UT Southwestern Medical Center, presented long-term results from the Orion…

At the 2026 meeting of the North American Neuromodulation Society in Las Vegas, Neurotech Reports editors, in conjunction with Nandan Lad from Duke University, produced a pre-conference workshop devoted to neurotech commercialization. The i3 program, which stands for invention, investment, and invigoration, is an opportunity for the neuromodulation community to explore business topics that aren’t generally covered in the meeting’s scientific sessions..

The ethical issues surrounding the use of animals in clinical trials and scientific experiments has been a source of controversy since the early days of medical research. For the neurotechnology industry, animal research—and primate research in particular—has been at the forefront of public awareness. The treatment of monkeys used ’s firm Neuralink generated a considerable amount of negative publicity a few years back.

Manufacturers of neurotechnology systems often look to a network of suppliers of components and engineering services to get their products to market faster and more economically. These supplier firms offer critical components such as batteries, housings, leads, and interconnects. Recently, several firms in this area made announcements or joined forces in an effort to attract more customers from the neurotech industry.

Much of the progress in bioelectronic medicine to date has been driven , whether the mode of stimulation was electrical, optical, ultrasound, or some other medium. But sensing and diagnostic technology is also important, in part to exploit new closed loop neuromodulation technologies, but also help determine the optimal therapeutic intervention, including pharmaceutical, device, or biologics approaches.

As 2026 begins, the neuromodulation industry has never been more exciting with a significant number of startup companies, applications, and innovations attracting investor interest. However, one sector continues to drag on the investment and valuation side, specifically spinal cord stimulation, a market more than six decades in the making that has reached a level of maturity where sustaining growth and defending valuations has become increasingly difficult.

The market for brain-computer interfaces continues to attract new entrants and new technologies, fueled in large part venture capital investment in the space. The latest U.S. entrant in this market is a spinoff from Columbia University called Kampto Neurotech. The company plans to commercialize a flexible, subdural brain implant with 65,000 electrodes and 1,024 channels. Fabricated as a single chip…

The month of January is generally a busy month for the neurotechnology industry and 2026 was no exception. Neurotech Reports’ editors participated in a number of events during and collected enough news and background information for a whole year’s worth of coverage, or so it seemed. The year began with a trip to Las Vegas for the CES show, where this editor and senior consulting editor Jeremy Koff surveyed numerous new product offerings in wearable and noninvasive technologies.

Transcutaneous electrical stimulation devices can be subdivided into three major categories: TENS, tVNS, and cranial electrotherapy stimulators, based on electrode placement on the body. TENS devices are used below the neck, tVNS devices are applied at the neck or ear, and CES devices are used above the neck. Although these devices are functionally similar, their FDA classifications differ significantly.